American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Immatics N.V.

$9.22 -5.82% NASDAQ: IMTX · 15-min delayed

Public · NASDAQ: IMTX
407 employees

Visit website Follow

$1.3BMarket cap

407Employees

IMTXNASDAQ

2020IPO

About Immatics N.V.

Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Company facts

Type: Public · NASDAQ: IMTX
Employees: 407
IPO date: Jul 2, 2020
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: IMTX Nasdaq
SEC CIK: 1809196
LEI: 984500DC691EZ96AF394
SIC: 2836 Biological Products, (No Diagnostic Substances)

Is this your company?

This profile is unclaimed — any authorized owner can claim it, control the page, and earn the Verified badge.

Claim this profile

Track American companies

Create a free account to follow Immatics N.V. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Market cap: $1.3B

NASDAQ: IMTX

$9.22 -5.82%

15-minute delayed · data by Polygon.io

Past year

$4.24 $11.87

52-week range

Market cap: $1.3B
Shares outstanding: 145.1M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Jul 2, 2020

Market data by Polygon.io · prices are 15-minute delayed

Auto-generated

At a glance

Trading 22% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Immatics N.V..

Write a review